Funding Daily Summary
Funding Daily Summary: What Happened on November 16, 2026
Sofinnova closes €725 million fund for later-stage biotech
Seawolf raised $100 million alongside a Sanofi partnership worth up to $1.2 billion. Flagship committed £100 million to a London-based AI venture lab.
Today in brief
Sofinnova Partners closed a €725 million fund for later-stage life-sciences companies, targeting about 15 businesses, mainly in Europe.12 The fund is 63% larger than its predecessor and has already backed Hemab Therapeutics, CellCentric and Neurent Medical.1
Seawolf Therapeutics secured $100 million from investors including Versant Ventures, Eli Lilly, MPM BioImpact and Novartis’ venture arm, and disclosed a Sanofi partnership worth up to $1.2 billion.34 Flagship Pioneering set aside £100 million for a London lab to create AI-focused companies, with an initial team of about 50 people planned.56
Sofinnova targets about 15 later-stage companies with €725 million fund
Sofinnova Partners closed its second crossover fund at €725 million, 63% larger than its first, to back biopharma and medical technology companies moving through clinical development toward commercialization.1 The firm expects to invest mainly in Europe, with selected investments in the United States and other markets, and plans to support about 15 companies.17
Crossover II has invested in Hemab Therapeutics, CellCentric and Neurent Medical, three European companies developing treatments for bleeding and clotting disorders, cancer, and chronic rhinitis, respectively.17 Sofinnova said companies backed by its first crossover fund later raised a combined €3.4 billion. That portfolio included businesses acquired by AstraZeneca, Asahi Kasei and Inari Medical.1
The fund will invest in private and publicly traded companies, and Sofinnova plans to retain capital for follow-on investments, the firm said.1 Partner Kinam Hong said European companies can face a capital shortage when they enter larger clinical trials and may need funding longer than expected, including when public markets are closed.1
Seawolf raises $100 million and discloses Sanofi deal worth up to $1.2 billion
Seawolf Therapeutics raised $100 million from investors including Versant Ventures, Eli Lilly, MPM BioImpact and Novartis’ venture arm.34 The company is developing ways to deliver genetic medicines without viruses. Viral vectors can trigger antibodies that prevent repeat dosing and can cause serious side effects at high doses.3
Seawolf also disclosed a partnership with Sanofi valued at up to $1.2 billion.4 Viral vectors have enabled gene delivery in several rare diseases and are being evaluated in hundreds of trials.3
Also worth knowing
Also published
- Atlas Venture 2026 Year In Review LifeSciVC